Sign up for email alert when new content gets added: Sign up
Objectives: Neuropathological evaluations are the gold standard for diagnosing a patient’s neurodegenerative disease and for validating biomarker tests. However, there may be a long delay between a biomarker determination and death. Plasma biomarker assays may provide a useful probabilistic determination of the identity of the causative condition and may easily be standardized across clinics. Unfortunately, validations of antemortem plasma biomarkers with postmortem neuropathology are rare. In this work, plasma was obtained from the Arizona Study of Aging and Neurodegenerative Disorders and Brain and Body Donation Program (AZSAND/BBDP) a longitudinal clinicopathological study that collects plasma antemortem and conducts autopsies after death.
+44 73620 49920
